Aclaris Therapeutics, Inc. (0H8T.L)
USD 3.14
(6.34%)
USD 3.14
(6.34%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 197.4 Million USD | -23.47% |
| 2022 | 257.95 Million USD | 2.69% |
| 2021 | 251.21 Million USD | 254.9% |
| 2020 | 70.78 Million USD | -27.99% |
| 2019 | 98.29 Million USD | -64.33% |
| 2018 | 275.56 Million USD | 12.19% |
| 2017 | 245.61 Million USD | 39.49% |
| 2016 | 176.08 Million USD | 87.17% |
| 2015 | 94.07 Million USD | 441.38% |
| 2014 | 17.37 Million USD | 22.31% |
| 2013 | 14.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 161.07 Million USD | -7.47% |
| 2024 Q1 | 174.06 Million USD | -12.77% |
| 2023 Q2 | 235.64 Million USD | 2.59% |
| 2023 Q1 | 229.7 Million USD | -10.95% |
| 2023 FY | 199.55 Million USD | -22.64% |
| 2023 Q4 | 199.55 Million USD | -8.61% |
| 2023 Q3 | 218.35 Million USD | -7.34% |
| 2022 Q2 | 277.97 Million USD | 22.71% |
| 2022 Q1 | 226.52 Million USD | -9.83% |
| 2022 Q3 | 267.63 Million USD | -3.72% |
| 2022 FY | 257.95 Million USD | 2.69% |
| 2022 Q4 | 257.95 Million USD | -3.61% |
| 2021 FY | 251.21 Million USD | 254.9% |
| 2021 Q2 | 288.04 Million USD | 78.47% |
| 2021 Q1 | 161.39 Million USD | 128.02% |
| 2021 Q4 | 251.21 Million USD | -4.66% |
| 2021 Q3 | 263.49 Million USD | -8.52% |
| 2020 Q2 | 84.99 Million USD | -12.2% |
| 2020 FY | 70.78 Million USD | -27.99% |
| 2020 Q4 | 70.78 Million USD | -1.55% |
| 2020 Q3 | 71.9 Million USD | -15.41% |
| 2020 Q1 | 96.81 Million USD | -1.51% |
| 2019 Q4 | 98.29 Million USD | -38.72% |
| 2019 Q3 | 160.41 Million USD | -26.16% |
| 2019 Q2 | 217.23 Million USD | -14.2% |
| 2019 Q1 | 253.18 Million USD | -8.12% |
| 2019 FY | 98.29 Million USD | -64.33% |
| 2018 Q4 | 275.56 Million USD | 56.42% |
| 2018 FY | 275.56 Million USD | 12.19% |
| 2018 Q1 | 220.62 Million USD | -9.4% |
| 2018 Q2 | 201.81 Million USD | -8.52% |
| 2018 Q3 | 176.17 Million USD | -12.71% |
| 2017 Q2 | 176.8 Million USD | 6.38% |
| 2017 FY | 245.61 Million USD | 39.49% |
| 2017 Q4 | 243.5 Million USD | -6.84% |
| 2017 Q1 | 166.21 Million USD | -5.61% |
| 2017 Q3 | 261.39 Million USD | 47.84% |
| 2016 FY | 176.08 Million USD | 87.17% |
| 2016 Q4 | 176.08 Million USD | 104.58% |
| 2016 Q3 | 86.07 Million USD | -10.43% |
| 2016 Q2 | 96.09 Million USD | 10.11% |
| 2016 Q1 | 87.27 Million USD | -7.23% |
| 2015 Q2 | 12.22 Million USD | 0.0% |
| 2015 Q3 | 42.08 Million USD | 244.33% |
| 2015 Q4 | 94.07 Million USD | 123.53% |
| 2015 FY | 94.07 Million USD | 441.38% |
| 2015 Q1 | - USD | -100.0% |
| 2014 Q4 | 17.37 Million USD | 0.0% |
| 2014 FY | 17.37 Million USD | 22.31% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 14.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 60.452% |
| Dynavax Technologies Corporation | 997.09 Million USD | 80.202% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 85.989% |
| Perrigo Company plc | 10.8 Billion USD | 98.174% |
| Illumina, Inc. | 10.11 Billion USD | 98.048% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.8% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 74.703% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.756% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.26% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 11.281% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.403% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -200.51% |
| Waters Corporation | 4.62 Billion USD | 95.733% |
| Biogen Inc. | 26.84 Billion USD | 99.265% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -19.408% |
| Evolus, Inc. | 188.99 Million USD | -4.448% |
| Adicet Bio, Inc. | 207.29 Million USD | 4.771% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -56.865% |
| bluebird bio, Inc. | 619.16 Million USD | 68.117% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 4.077% |
| FibroGen, Inc. | 423.52 Million USD | 53.39% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.166% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -598.225% |
| Homology Medicines, Inc. | 47.05 Million USD | -319.502% |
| Geron Corporation | 394.07 Million USD | 49.907% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 94.846% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 74.623% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 83.532% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 46.429% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 84.826% |
| Zoetis Inc. | 14.28 Billion USD | 98.618% |
| Abeona Therapeutics Inc. | 64 Million USD | -208.436% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 94.117% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 97.115% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.132% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -252.83% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 93.398% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -19.275% |
| Verastem, Inc. | 149.71 Million USD | -31.851% |
| Nektar Therapeutics | 398.03 Million USD | 50.405% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 66.441% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 93.953% |
| OPKO Health, Inc. | 2.01 Billion USD | 90.187% |
| Exelixis, Inc. | 2.94 Billion USD | 93.291% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 93.929% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 68.238% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -27.865% |
| uniQure N.V. | 831.68 Million USD | 76.265% |
| Imunon, Inc. | 21.91 Million USD | -800.65% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 81.186% |
| Insmed Incorporated | 1.32 Billion USD | 85.156% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 88.611% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 78.935% |
| TG Therapeutics, Inc. | 329.58 Million USD | 40.105% |
| Incyte Corporation | 6.78 Billion USD | 97.089% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 89.242% |